For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Corcept Therapeutics (CORT) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.Corcept Therapeutics is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to w ...

Shares of Corcept Therapeutics Incorporated (CORT) have rallied 56.4% in the past six months against the industry’s decline of 10.5%.The company’s sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome or endogenous hypercortisolism, has been performing well. The drug has been witnessing strong demand in recent quarters and the trend is likely to continue in 2025.The company’s top line solely comprises product sales from Korlym. Sales of the drug increased almost 40% ye ...

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated regarding potential securities fraud or unlawful business practices [1] - A lawsuit has been filed against Corcept by a group of health insurers, alleging manipulation of the patent process to hinder Teva Pharmaceutical's generic product launch of Korlym [2] - Following the news of the lawsuit, Corcept's stock price experienced a significant decline of $8.44 per share, or 11.48%, closing at $65.09 per share [3] Company Overview - Corcept Therapeutics is known for its product Korlym, which has been a best-seller in its category [2] - The company is facing legal challenges that may impact its market position and stock performance [2][3] Legal Context - The lawsuit against Corcept highlights ongoing tensions in the pharmaceutical industry regarding patent enforcement and competition from generic drugs [2] - Pomerantz LLP, a prominent firm in corporate and securities litigation, is leading the investigation into Corcept's practices [1][4]

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth S ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Corcept Therapeutics (CORT) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Corcept Therapeutics is a member of our Medical group, which includes 1009 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring t ...

Corcept Therapeutics Incorporated (CORT) reported fourth-quarter 2024 earnings of 26 cents per share, which missed the Zacks Consensus Estimate of 37 cents. The company had reported earnings of 28 cents per share in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Revenues in the fourth quarter increased 34.3% year over year to $181.9 million. However, the figure missed the Zacks Consensus Estimate of $196 million. The top line solely comprises product sales of the Cu ...

Financial Data and Key Metrics Changes - The company's revenue for 2024 was $675 million, representing a 40% increase compared to the previous year [4] - Net income for 2024 was $141 million, an increase of 33% year-over-year [5] - Cash and investments at the end of 2024 were $603 million, up from $425 million at the end of the previous year [5] - The company provided revenue guidance for 2025 of $900 million to $950 million [5] Business Line Data and Key Metrics Changes - The number of new Korlym prescribers and patients receiving Korlym reached record levels throughout 2024 [10] - The CATALYST study indicated that hypercortisolism is more prevalent than previously assumed, with 1 in 4 patients with difficult-to-control type 2 diabetes affected [20] - In the CATALYST treatment phase, patients receiving Korlym showed a significant reduction in hemoglobin A1c by 1.47% compared to a 0.15% decrease in the placebo group [21] Market Data and Key Metrics Changes - The company noted that the prevalence of hypercortisolism is higher than historical estimates, with the FDA agreeing on the increased patient population [80] - The company anticipates that the market for hypercortisolism treatments could grow from $3 billion to $5 billion in annual revenues within 3 to 5 years [81] Company Strategy and Development Direction - The company is focused on increasing physician awareness of hypercortisolism and expanding its treatment offerings, including relacorilant [20][40] - A new drug application for relacorilant was submitted, based on positive results from clinical studies [12][41] - The company is also exploring relacorilant's potential in oncology, particularly in ovarian cancer and prostate cancer [24][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued revenue growth and the effectiveness of their treatments for hypercortisolism [5][39] - The operational challenges faced by their pharmacy partner were acknowledged, but management is optimistic about resolving these issues [78] - The company expects to see a significant impact from the CATALYST study data in the second half of the year and beyond [68] Other Important Information - The company is conducting multiple studies, including the ROSELLA study for ovarian cancer and the MOMENTUM study for resistant hypertension [27][23] - The safety profile of relacorilant was highlighted, with no serious adverse events reported [19] Q&A Session Summary Question: When should the company expect NDA acceptance for relacorilant? - The NDA was submitted on December 30, and the FDA has 60 days to review it for acceptance, with routine correspondence ongoing [49][50] Question: What is the status of the ROSELLA trial and the change in endpoints? - The change to dual primary endpoints was made in collaboration with the FDA, allowing for two chances for a positive outcome [74] Question: How is the CATALYST study impacting patient screening and treatment? - Initial impacts are being observed, with expectations for more significant changes in medical practice as more data is published [68]

Corcept Therapeutics (CORT) Q4 2024 Earnings Call February 27, 2025 03:37 AM ET Company Participants Atabak Mokari - Chief Financial OfficerCharles Robbins - Chief Business OfficerJoseph Belanoff - Chief Executive Officer, President and DirectorWilliam Guyer - Chief Development OfficerSean Maduck - President of Endocrinology Conference Call Participants David Amsellem - Sr. Research AnalystRamakanth Swayampakula - Managing Director & Senior Research AnalystAsim Rana - Equity Analyst Operator Thank you for s ...

Core Insights - Corcept Therapeutics reported quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.37 per share, and showing a decrease from $0.28 per share a year ago, resulting in an earnings surprise of -29.73% [1] - The company posted revenues of $181.89 million for the quarter ended December 2024, which was 7.08% below the Zacks Consensus Estimate, but an increase from $135.41 million year-over-year [2] - Corcept has surpassed consensus EPS estimates three times over the last four quarters, indicating a mixed trend in estimate revisions ahead of the earnings release [2][6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.39 on revenues of $189.08 million, and for the current fiscal year, it is $1.85 on revenues of $811.91 million [7] - The stock has outperformed the S&P 500, gaining about 21.5% since the beginning of the year compared to the S&P 500's gain of 1.3% [3] - The Zacks Industry Rank for Medical - Drugs is in the top 50% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8] Industry Context - Recursion Pharmaceuticals, another company in the same industry, is expected to report a quarterly loss of $0.36 per share, with revenues projected at $28.73 million, reflecting a year-over-year increase of 163.9% [9][10]